CRE After ERCP: A Duodenoscope Reprocessing Breach

Treat this as a possible device-related outbreak: protect patients now, then investigate.

• Convene infection prevention, endoscopy, microbiology, and risk management. Define a case (CRE isolated from a patient with prior ERCP in the exposure window) and build a line list with procedure dates, scopes used, reprocessing records, and microbiology.
• Quarantine both duodenoscopes. Remove them from service and do not reuse until cultured or cleared. Send scopes for culture and/or manufacturer-recommended surveillance, and consider returning the repaired scope for inspection.
• Observe reprocessing directly, step by step: point-of-use pre-cleaning, leak testing, manual cleaning including the elevator mechanism and correct brush size, flushing, high-level disinfection concentration and contact time, rinsing, alcohol flush, and drying. Review logs, but recognize that logs document time, not technique. The ten-second brush observation and the non-HEPA drying cabinet are plausible breach points.
• Notify the local public health department and, if indicated, the state; contact the manufacturer and FDA MedWatch if a device defect is suspected.
• Cohort or suspend ERCP until reprocessing is verified. Urgent cases should be transferred or performed with a scope that has been cultured and cleared.

Reasoning: CRE transmission by duodenoscopes is well documented even when reprocessing appears compliant, so the safe assumption is that a breach has not been excluded. Quarantine and direct observation come first because every additional ERCP adds exposed patients.

Yes, notify the 46 patients, and do it proactively. The decision does not require proof that the scope transmitted infection; it requires a plausible exposure and a potential harm that patients cannot assess themselves. The hospital knows three patients developed CRE after ERCP, one scope had incomplete records, and reprocessing practice deviated from the manufacturer's instructions. Waiting for confirmation delays screening and erodes trust.

How to proceed:

• Risk management, infection prevention, and communications draft a letter with clinical input: what happened in plain language, what is known and unknown, what screening is recommended (typically a rectal or stool culture or PCR for CRE, with timing based on exposure), symptoms to watch for, and a phone number for questions.
• Offer testing at no cost, notify primary care providers, and set up a results and follow-up pathway, including treatment if positive.
• Coordinate with legal and public health about disclosure obligations; document the decision and rationale.
• Do not overstate or minimize. Saying 'CRE is endemic' is an epidemiologic observation, not a reason to withhold information about a device-related exposure.

Reasoning: notification is a harm-reduction and duty-to-warn decision. The cost of notifying is anxiety and phone calls; the cost of not notifying is untreated infection and lost credibility. Suspending ERCP until the reprocessing review is complete is the parallel decision, because continuing the service while the breach is unresolved exposes new patients.

Single fixes, such as a new drying cabinet or a reminder poster, will not hold. The failure here looks systemic: technique variation, incomplete records, storage conditions, and a repaired scope returned to service without verification.

Changes:

• Standardize reprocessing with a checklist and direct-observation competency at hire and annually; require a second person to verify critical steps for duodenoscopes.
• Use scopes with FDA-cleared designs and follow current manufacturer instructions for use, including any FDA-recommended supplemental measures; budget for replacement and redundancy.
• Improve drying and storage: HEPA-filtered drying cabinet, vertical hanging, and a defined maximum storage time.
• Make records complete and auditable: scope ID, patient ID, reprocessor, cycle parameters, and exceptions.
• Establish surveillance: culture scopes per policy, track ERCP-related infections, and review clusters monthly.
• Empower staff to stop the line when reprocessing cannot be done correctly.

How to know it worked: the metric is not 'logs complete' but observed adherence to every critical step plus absence of new CRE signals in ERCP patients. Report both to the safety committee and infection prevention committee quarterly.